Literature DB >> 9600821

A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer.

G Thomas1, A Dembo, I Ackerman, E Franssen, J Balogh, A Fyles, W Levin.   

Abstract

The objective of this study was to determine whether the addition of concurrent 5-fluorouracil (5-FU) and/or a change in radiation fractionation improves pelvic control and survival or decreases complications in advanced cervical cancer, FIGO stages IB/IIA (>=5 cm) to IVA inclusive. After stratification by pelvic disease extent, 234 of a planned 292 patients were randomized to receive one of four possible treatments: (a) standard external beam pelvic irradiation (RT) 5000 cGy in 25 fractions versus (b) RT as in arm (a) with infusional IV 5-FU 1g/m2 daily in the first and last 4 days of RT, (c) partially hyperfractionated RT, 5280 cGy in 33 fractions, two fractions per day on the first and last 4 days of RT, or (d) arm (c) with the same FU. All were followed with a linear source of intracavitary RT to deliver 40 Gy. The median duration of follow-up for the 221 evaluable patients was 59 months. The 5-year Kaplan-Meier disease-free survival (DFS) in arm (a), (c), (d), and (b), respectively, were 45, 53, 58, and 61%. The differences in survival and pelvic control were not statistically significant. An exploratory subset analysis was performed within stratum 1 and stratum 2 to generate hypotheses for future studies. Only for the 99 patients in stratum 1 (IB/IIA or medial parametrial IIB disease) was the 5-year DFS significantly better (long rank P = 0.05) for standard RT and 5-FU. The DFS was 39% for arm (a), 76% for arm (b), 58% for arm (c), and 65% for arm (d). A multivariate analysis of patient, tumor, and treatment related prognostic factors identified only the use of 5-FU to account for the observed difference. The crude serious late bowel or bladder complication rate was 5.9%. Overall concurrent infusional 5-FU was not beneficial when added to standard RT in this study. The possible benefit for patients in stratum 1 requires exploration in a further randomized trial with appropriate accrual. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600821     DOI: 10.1006/gyno.1998.4990

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

Review 1.  Concurrent chemotherapy and radiation therapy in primary cancer of the cervix.

Authors:  J M Schilder; F B Stehman
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

2.  [Simultaneous radiochemotherapy with cisplatin improves survival in cervical cancer].

Authors:  J Dunst; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

3.  Pelvic irradiation modulates the pharmacokinetics of cisplatin in the plasma and lymphatic system.

Authors:  Tung-Hu Tsai; Yu-Jen Chen; Mei-Ling Hou; Li-Ying Wang; Hung-Chi Tai; Chen-Hsi Hsieh
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

4.  Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly cisplatin in locally advanced carcinoma cervix.

Authors:  Pragyat Thakur; Rajeev Seam; Manoj Gupta; Manish Gupta
Journal:  Ann Transl Med       Date:  2016-02

5.  Chemoradiotherapy: the new standard care for invasive cervical cancer.

Authors:  P G Rose
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 6.  Pharmacotherapy options for locally advanced and advanced cervical cancer.

Authors:  Alfonso Dueñas-González; Lucely Cetina; Jaime Coronel; Déborah Martínez-Baños
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

Review 7.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

8.  Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone.

Authors:  Koji Matsuo; David J Nusbaum; Hiroko Machida; Yongmei Huang; Varun Khetan; Shinya Matsuzaki; Maximilian Klar; Brendan H Grubbs; Lynda D Roman; Jason D Wright
Journal:  Am J Obstet Gynecol       Date:  2019-10-31       Impact factor: 8.661

Review 9.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.

Authors: 
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

10.  Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer.

Authors:  Tae Wook Kong; Suk-Joon Chang; Jiheum Paek; Seung-Chul Yoo; Jong-Hyuck Yoon; Ki-Hong Chang; Mison Chun; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.